Company intelligence / Profile preview

Thrive Earlier Detection

Cambridge, Massachusetts, United Statesthrivedetect.com ↗

Ownership: Private
Employees: ~80
Development stage: Other

Overview

CancerSEEK, Thrive's core multi-cancer early detection liquid biopsy test, showed greater than 99% specificity and 69–98% sensitivity for 5 cancer types lacking screening tools. In the DETECT-A study (n≈10,000), combining CancerSEEK with standard of care screening substantially improved overall detection rates for multiple early cancers[1][4][8].

Therapeutic areas: Oncology
Modalities: DeviceDiagnosticsLiquid biopsy
Industry: Molecular Diagnostics

Partnerships

Johns Hopkins UniversityGeisinger Health

Beyond the preview

Go deeper on Thrive Earlier Detection.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Thrive Earlier Detection.

Explore the full profile